NeuroXess

NeuroXess announced a RMB 700 million Series B round co-led by Guotou Juli, Shenzhen Capital Group, and Qinzhi Capital. The company says proceeds will support multicenter registration trials and regulatory approval work for its fully implantable, fully wireless, fully functional BCI system, manufacturing facilities, next-generation products, and BCI–AI integration. It reports that the registration trial has started at Huashan Hospital, Fudan University, and that its planned factory covers 14,300 square meters, targeting production capacity on the scale of 10,000 systems. These clinical and manufacturing updates are company disclosures: starting a registration trial does not mean device approval, and planned capacity is not current output.

NeuroXess reported that Xiao Jia, a participant with tetraplegia whose name is a pseudonym, used an implanted brain-computer interface with large AI models and 3D printing to turn brain-controlled sketches and text prompts into a physical figurine. He also helped create a personalized finger sleeve for tablet use. According to the company, he proposed ideas, compared options and made selections, while AI generated designs and digital models. In environmental interaction tasks, AI smart glasses identified objects and offered device-control options. After he expressed and confirmed his intention through the BCI, the system adjusted a bed and controlled lighting and household devices. These are application explorations involving this participant, not evidence of restored motor function.

NeuroXess announced that its self-developed implantable brain-computer interface system for hand motor function compensation — the 'fully implanted, fully wireless, fully functional' ('Sanquan') system — has passed public notice and formally entered the innovative medical device special review program of the National Medical Products Administration's Center for Medical Device Evaluation (CMDE), commonly known as the green channel. The company describes it as the first subdural implantable flexible BCI product in China to enter the program. The system began a GCP registration clinical trial at Huashan Hospital, Fudan University on July 7, 2026, run as a multicentre study across 15 Class III hospitals nationwide, with trial data intended to support a Class III medical device registration application with the NMPA. The system remains in the review and clinical-trial stage and has not yet been approved for market; the registration timeline reflects company statements and remains subject to regulatory notice.

NeuroXess announced the launch of a GCP registration clinical trial at Huashan Hospital, Fudan University, for its implantable BCI system for hand motor function compensation. The trial aims to evaluate safety and efficacy for upper limb function compensation in people with tetraplegia caused by cervical spinal cord injury. According to the company, Professor Mao Ying's team serves as the principal investigator team, and the multicenter study involves 15 Grade III Class A hospitals. Data will support a Class III medical device registration application to the National Medical Products Administration. The system uses flexible electrodes on the cortical surface beneath the dura, with battery, wireless transmission and charging units under the skin of the chest. The announcement concerns trial initiation, not regulatory approval or demonstrated efficacy.

NeuroXess said two people with high-level paralysis played chess against each other across about 800 kilometers, between Shanghai and Nanchang in eastern China, using its "Triple-Full" (三全) brain-computer interface: one selected and placed pieces on a virtual board by thought, with the commands relayed in real time to a robot stand-in that moved the pieces at the other end, where the second participant gripped physical pieces through a brain-controlled exoskeleton glove. The company said the first participant was implanted at Huashan Hospital, Fudan University, in October 2025, moved a cursor by thought on the fifth day after surgery and reached 5.2 bits per second after 17 days of training, while the second was implanted at the First Affiliated Hospital of Nanchang University in December 2025 and was eating, drinking and writing with a brain-controlled exoskeleton one month after surgery. The outcomes come from the vendor's own account and have not been validated in peer-reviewed publication.